NCT02301130 2024-04-25Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid TumorsKyowa Kirin Co., Ltd.Phase 1 Completed64 enrolled
NCT02281409 2021-04-23Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid TumorsMemorial Sloan Kettering Cancer CenterPhase 1/2 Completed17 enrolled 13 charts